journal article·2021-01Open access

Virus-associated ribozymes and nano carriers against COVID-19

Beyza Dönmüş, Sinan Ünal, Fatma Ceren Kirmizitaş, Nelisa Türkoğlu Laçin

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoo tonic, highly pathogenic virus. The new type of coronavirus with contagious nature spread from Wuhan (China) to the whole world in a very short time and caused the new coronavirus disease (COVID-19). COVID-19 has turned into a global public health crisis due to spreading by close person-to-person contact with high transmission capacity. Thus, research about the treatment of the damages caused by the virus or prevention from infection increases everyday. Besides, there is still no approved and definitive, standardized treatment for COVID-19. However, this disaster experienced by human beings has made us realize the significance of having a system ready for use to prevent humanity from viral attacks without wasting time. As is known, nanocarriers can be targeted to the desired cells in vitro and in vivo. The nano-carrier system targeting a specific protein, containing the enzyme inhibiting the action of the virus can be developed. The system can be used by simple modifications when we encounter another virus epidemic in the future. In this review, we present a potential treatment method consisting of a nanoparticle-ribozyme conjugate, targeting ACE-2 receptors by reviewing the virus-associated ribozymes, their structures, types and working mechanisms.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Molecular Biology and Genetics Department, Yıldız Technical University, Istanbul, Turkey

References (100+)

Show source-provided references
1. 10.1046/j.1440-1843.2003.00516.x10.1046/j.1440-1843.2003.00516.x ↗
2. 10.5144/0256-4947.2013.42710.5144/0256-4947.2013.427 ↗
3. 10.1016/j.jare.2020.03.00510.1016/j.jare.2020.03.005 ↗
4. 10.1016/j.jinf.2020.12.02410.1016/j.jinf.2020.12.024 ↗
5. 10.1016/S1473-3099(20)30840-910.1016/S1473-3099(20)30840-9 ↗
6. 10.1371/journal.pone.023476510.1371/journal.pone.0234765 ↗
7. Turan C, Hacımustafaoğlu M. What is the R0 number and clinical significance in infectious diseases? Cocuk Enfeksiyon Derg. 2020;14(1):e47–e48.
8. 10.1056/NEJMoa200131610.1056/NEJMoa2001316 ↗
9. 10.3201/eid2606.20023910.3201/eid2606.200239 ↗
10. 10.1016/S0140-6736(20)30154-910.1016/S0140-6736(20)30154-9 ↗
11. 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 ↗
12. 10.7326/M20-301210.7326/M20-3012 ↗
13. 10.1016/j.ijid.2020.08.07610.1016/j.ijid.2020.08.076 ↗
14. 10.1371/journal.pone.024153610.1371/journal.pone.0241536 ↗
15. Byambasuren O, Cardona M, Bell K, et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Off J Assoc Med Microbiol Infect Dis Canada. 2020;5(4): 223–234.
16. 10.1002/lary.2920710.1002/lary.29207 ↗
17. Alimohamadi Y, Sepandi M, Taghdir M, et al. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020;61(3):E304.
18. 10.1007/s15010-020-01516-210.1007/s15010-020-01516-2 ↗
19. 10.4065/mcp.2011.030910.4065/mcp.2011.0309 ↗
20. 10.1186/1471-2334-14-S5-S110.1186/1471-2334-14-S5-S1 ↗
21. 10.1186/s12929-019-0611-010.1186/s12929-019-0611-0 ↗
22. Wei ZX, Tang TT, Jiang SP. The antiviral mechanisms, effects, safety and adverse effects of chloroquine. Eur Rev Med Pharmacol Sci. 2020;24(12):7164-7172..
23. 10.4254/wjh.v9.i5.22710.4254/wjh.v9.i5.227 ↗
24. 10.1517/17425255.2015.99899710.1517/17425255.2015.998997 ↗
25. Corrall-Gudino L, Bahamonde A, de las Revillas FA, et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020.
26. 10.1016/j.ijantimicag.2020.10594910.1016/j.ijantimicag.2020.105949 ↗
27. Thammathiwat T, Tungsanga S, Tiankanon K, et al. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient. Transpl Infect Dis. 2020; e13388.
28. Mallmann G O’Neill HSC. The crystal/melt partitioning of V during mantle melting as a function of oxygen fugacity compared with some other elements (Al P Ca Sc Ti Cr Fe Ga Y Zr and Nb). Journal of Petrology. 2009; 50(9):1765–1794.10.1093/petrology/egp053 ↗
29. 10.1073/pnas.200561511710.1073/pnas.2005615117 ↗
30. 10.1186/s40779-020-00296-y10.1186/s40779-020-00296-y ↗
31. 10.1038/d41573-021-00002-010.1038/d41573-021-00002-0 ↗
32. Vaccines & Immunizations. Centers for Disease Control and Prevention. 2020. [Online]; [cited 2020 Jan 18]. Available from: www.cdc.gov/ncird/overview/index.html
33. Mahase E. Covid-19: what do we know about the late stage vaccine candidates? BMJ. 2020:371:m4576 .
34. 10.1080/13543776.2021.186124810.1080/13543776.2021.1861248 ↗
35. 10.1093/cid/ciaa87910.1093/cid/ciaa879 ↗
36. 10.1007/s40265-020-01378-w10.1007/s40265-020-01378-w ↗
37. 10.3390/cells901013710.3390/cells9010137 ↗
38. 10.1016/j.omtn.2020.04.01210.1016/j.omtn.2020.04.012 ↗
39. Jain S, Kaur J, Prasad S, et al. Nucleic acid therapeutics: a focus on the development of aptamers. Expert Opin Drug Discov. 2020;1-20.
40. 10.1039/D0CS00617C10.1039/D0CS00617C ↗
41. 10.1007/s10555-017-9717-610.1007/s10555-017-9717-6 ↗
42. 10.1146/annurev-pharmtox-010715-10363310.1146/annurev-pharmtox-010715-103633 ↗
43. 10.1038/s41573-019-0017-410.1038/s41573-019-0017-4 ↗
44. Gündoğdu R Çelik V. RNA interferans (RNAi). Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi.2009; 25(1): 34-47.
45. 10.1208/s12248-009-9159-310.1208/s12248-009-9159-3 ↗
46. 10.1128/JVI.02933-1410.1128/JVI.02933-14 ↗
47. 10.1038/s41586-020-2639-410.1038/s41586-020-2639-4 ↗
48. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
49. Liu Z Wang J Xu Y et al. Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2. rXiv preprint arXiv:2004.04874. 2020.
50. 10.1105/tpc.113.10925610.1105/tpc.113.109256 ↗
51. Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for covid-19. EXCLI J. 2020;19:528–531.
52. 10.1517/1471259090344815810.1517/14712590903448158 ↗
53. 10.1007/s12250-020-00221-610.1007/s12250-020-00221-6 ↗
54. 10.1631/jzus.B170059410.1631/jzus.B1700594 ↗
55. Pasquier C Robichon A. SARS-CoV-2 might manipulate against its host the immunity RNAi/Dicer/Ago system. Does mitochondria collapse upon COVID-19 infection? 2020. 1–15.
56. Barrey E Burzio V Dhorne-Pollet S et al. Think different with RNA therapy: can antisense oligonucleotides be used to inhibit replication and transcription of SARS-Cov-2? . Preprints. 2020. 1–23.10.20944/preprints202004.0412.v1 ↗
57. Germer K, Leonard M, Zhang X. RNA aptamers and their therapeutic and diagnostic applications. Int J Biochem Mol Biol. 2013;4(1):27–40.
58. 10.1039/b906788d10.1039/b906788d ↗
59. 10.1016/0092-8674(82)90414-710.1016/0092-8674(82)90414-7 ↗
60. 10.1016/S0168-6445(03)00020-210.1016/S0168-6445(03)00020-2 ↗
61. 10.1159/00021594610.1159/000215946 ↗
62. 10.1038/418222a10.1038/418222a ↗
63. Tanner MA, Cech TR. An important RNA tertiary interaction of group I and group II introns is implicated in gram-positive RNase P RNAs. RNA. 1995;1(4):349–350.
64. 10.1038/nrm164710.1038/nrm1647 ↗
65. 10.1146/annurev.biophys.30.1.45710.1146/annurev.biophys.30.1.457 ↗
66. Elliott D, Ladomery M. Molecular biology of RNA. Oxford University Press UK. 2017.
67. 10.1038/nrmicro149110.1038/nrmicro1491 ↗
68. 10.1016/j.tibs.2006.04.00710.1016/j.tibs.2006.04.007 ↗
69. 10.1016/j.cell.2008.09.01310.1016/j.cell.2008.09.013 ↗
70. 10.1073/pnas.96.14.780310.1073/pnas.96.14.7803 ↗
71. 10.1093/nar/gkz01810.1093/nar/gkz018 ↗
72. 10.1016/B978-0-12-381286-5.00001-910.1016/B978-0-12-381286-5.00001-9 ↗
73. 10.1186/1471-2105-7-48010.1186/1471-2105-7-480 ↗
74. 10.1128/JVI.79.6.3728-3736.200510.1128/JVI.79.6.3728-3736.2005 ↗
75. 10.1080/1528739090308431410.1080/15287390903084314 ↗
76. 10.1099/vir.0.2008/001222-010.1099/vir.0.2008/001222-0 ↗
77. 10.1006/viro.2000.053610.1006/viro.2000.0536 ↗
78. 10.1038/nm.193210.1038/nm.1932 ↗
79. 10.1002/jmv.189042041110.1002/jmv.1890420411 ↗
80. 10.1038/nature0711710.1038/nature07117 ↗
81. 10.3390/molecules2201007810.3390/molecules22010078 ↗
82. 10.1261/rna.031401.11110.1261/rna.031401.111 ↗
83. 10.1007/s00018005024710.1007/s000180050247 ↗
84. 10.1517/13543776.2013.82315910.1517/13543776.2013.823159 ↗
85. 10.1128/JVI.02650-0510.1128/JVI.02650-05 ↗
86. Been MD. HDV ribozymes. Curr Top Microbiol Immunol. 2006;307:47–65.
87. Riccitelli N, Luptak A. HDV family of self-cleaving ribozymes. Progress in molecular biology and translational science. 2013;120.:123–171.
88. 10.1016/j.tibs.2015.09.00110.1016/j.tibs.2015.09.001 ↗
89. 10.1006/jmbi.2000.356010.1006/jmbi.2000.3560 ↗
90. 10.1016/j.jmb.2004.04.06710.1016/j.jmb.2004.04.067 ↗
91. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Progress in nucleic acid research and molecular biology. 1997;58:1–39.
92. 10.1385/MB:12:1:11710.1385/MB:12:1:117 ↗
93. 10.1016/S0042-6822(95)80053-010.1016/S0042-6822(95)80053-0 ↗
94. 10.1038/nchembio.158710.1038/nchembio.1587 ↗
95. 10.1073/pnas.141457111110.1073/pnas.1414571111 ↗
96. 10.1021/jacs.5b1206110.1021/jacs.5b12061 ↗
97. 10.1073/pnas.100425510710.1073/pnas.1004255107 ↗
98. 10.1261/rna.521710410.1261/rna.5217104 ↗
99. 10.1101/cshperspect.a00357410.1101/cshperspect.a003574 ↗
100. 10.1017/S003358351000014410.1017/S0033583510000144 ↗